Literature DB >> 21713542

Determinants of spirometry use and accuracy of COPD diagnosis in primary care.

Min J Joo1, David H Au, Marian L Fitzgibbon, Joanne McKell, Todd A Lee.   

Abstract

BACKGROUND: It is unclear if primary care physicians are following guidelines or using other patient characteristics and factors to determine when to perform spirometry in patients at risk for COPD. It is also unclear to what degree a diagnosis of COPD is accurately reflected by spirometry results.
OBJECTIVES: To examine characteristics associated with use of spirometry in primary care for patients with increased risk for COPD and to determine the accuracy of COPD diagnosis in patients with spirometry.
DESIGN: Retrospective cohort study.
SUBJECTS: A cohort that met the following criteria was identified: ≥35 years of age; ≥ 2 primary care visits in internal medicine clinic in 2007; at least one respiratory or smoking cessation medication, or diagnosis of COPD or shortness of breath or dyspnea in 2007. MAIN MEASURES: Medical records of all primary care physician visits prior to the time of inclusion in 2007 were reviewed. Data on patient demographics, co-morbidities, respiratory medication use, presence of symptoms, history of tobacco use, and pulmonary function tests were extracted. KEY
RESULTS: A total 1052 patients were identified. Dyspnea on exertion (Adjusted odds ratio (AOR) 1.52 [95% CI 1.06-2.18]) and chronic cough (AOR 1.71 [1.07-2.72]) were the only chronic symptoms associated with use of spirometry. Current (AOR 1.54 [0.99-2.40]) or past smoking (AOR 1.09 [0.72-1.65]) status were not associated with use of spirometry. Of the 159 patients with a diagnosis of COPD, 93 (58.5%) met GOLD criteria and 81(50.9%) met lower limit of normal (LLN) criteria for COPD.
CONCLUSION: Clinicians use spirometry more often among patients with symptoms suggestive of COPD but not more often among patients with current or past tobacco use. For patients who had a spirometry and a diagnosis of COPD, primary care physicians were accurate in their diagnosis only half of the time.

Entities:  

Mesh:

Year:  2011        PMID: 21713542      PMCID: PMC3208468          DOI: 10.1007/s11606-011-1770-1

Source DB:  PubMed          Journal:  J Gen Intern Med        ISSN: 0884-8734            Impact factor:   5.128


  31 in total

1.  Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper.

Authors:  B R Celli; W MacNee
Journal:  Eur Respir J       Date:  2004-06       Impact factor: 16.671

2.  Quality of life changes in COPD patients treated with salmeterol.

Authors:  P W Jones; T K Bosh
Journal:  Am J Respir Crit Care Med       Date:  1997-04       Impact factor: 21.405

3.  Use of a long-acting inhaled beta2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease.

Authors:  S I Rennard; W Anderson; R ZuWallack; J Broughton; W Bailey; M Friedman; M Wisniewski; K Rickard
Journal:  Am J Respir Crit Care Med       Date:  2001-04       Impact factor: 21.405

4.  Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease.

Authors:  Robert Wise; John Connett; Gail Weinmann; Paul Scanlon; Melissa Skeans
Journal:  N Engl J Med       Date:  2000-12-28       Impact factor: 91.245

5.  Salmeterol reduces dyspnea and improves lung function in patients with COPD.

Authors:  A Ramirez-Venegas; J Ward; T Lentine; D A Mahler
Journal:  Chest       Date:  1997-08       Impact factor: 9.410

Review 6.  Regular inhaled short acting beta2 agonists for the management of stable chronic obstructive pulmonary disease: Cochrane systematic review and meta-analysis.

Authors:  F S F Ram; P Sestini
Journal:  Thorax       Date:  2003-07       Impact factor: 9.139

Review 7.  The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review of randomized placebo-controlled trials.

Authors:  Abdullah Alsaeedi; Don D Sin; Finlay A McAlister
Journal:  Am J Med       Date:  2002-07       Impact factor: 4.965

8.  Effects of formoterol and ipratropium bromide in COPD: a 3-month placebo-controlled study.

Authors:  M Wadbo; C G Löfdahl; K Larsson; B E Skoogh; G Tornling; E Arweström; T Bengtsson; K Ström
Journal:  Eur Respir J       Date:  2002-11       Impact factor: 16.671

9.  Fracture risk associated with inhaled corticosteroid use in chronic obstructive pulmonary disease.

Authors:  Todd A Lee; Kevin B Weiss
Journal:  Am J Respir Crit Care Med       Date:  2004-01-07       Impact factor: 21.405

10.  A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol.

Authors:  James F Donohue; Jan A van Noord; Eric D Bateman; Stephen J Langley; Angela Lee; Theodore J Witek; Steven Kesten; Lesley Towse
Journal:  Chest       Date:  2002-07       Impact factor: 9.410

View more
  14 in total

1.  Factors predictive of airflow obstruction among veterans with presumed empirical diagnosis and treatment of COPD.

Authors:  Bridget F Collins; Laura C Feemster; Seppo T Rinne; David H Au
Journal:  Chest       Date:  2015-02       Impact factor: 9.410

2.  Clinical relevance of fixed ratio vs lower limit of normal of FEV1/FVC in COPD: patient-reported outcomes from the CanCOLD cohort.

Authors:  Wouter van Dijk; Wan Tan; Pei Li; Best Guo; Summer Li; Andrea Benedetti; Jean Bourbeau
Journal:  Ann Fam Med       Date:  2015 Jan-Feb       Impact factor: 5.166

3.  Spirometry use among older adults with chronic obstructive pulmonary disease: 1999-2008.

Authors:  Shawn P E Nishi; Yue Wang; Yong-Fang Kuo; James S Goodwin; Gulshan Sharma
Journal:  Ann Am Thorac Soc       Date:  2013-12

4.  Multicenter study comparing case definitions used to identify patients with chronic obstructive pulmonary disease.

Authors:  Valentin Prieto-Centurion; Andrew J Rolle; David H Au; Shannon S Carson; Ashley G Henderson; Todd A Lee; Peter K Lindenauer; Mary A McBurnie; Richard A Mularski; Edward T Naureckas; William M Vollmer; Binoy J Joese; Jerry A Krishnan
Journal:  Am J Respir Crit Care Med       Date:  2014-11-01       Impact factor: 21.405

5.  Point of Care Portable Spirometry in the Diagnosis and Treatment of Inpatients with Chronic Obstructive Pulmonary Disease.

Authors:  Donald Tran; Melvin Lim; Sara Vogrin; Lata Jayaram
Journal:  Lung       Date:  2020-01-01       Impact factor: 2.584

6.  Comorbid Anxiety and Depression, Though Underdiagnosed, Are Not Associated with High Rates of Low-Value Care in Patients with Chronic Obstructive Pulmonary Disease.

Authors:  Matthew F Griffith; Hung-Yuan P Chen; David B Bekelman; Laura C Feemster; Laura J Spece; Lucas M Donovan; David H Au; Evan P Carey
Journal:  Ann Am Thorac Soc       Date:  2021-03

7.  Accuracy of the COPD diagnostic questionnaire as a screening tool in primary care.

Authors:  Lisa Pagano; Zoe McKeough; Sally Wootton; Nicholas Zwar; Sarah Dennis
Journal:  BMC Prim Care       Date:  2022-04-14

8.  Assessment of five different guideline indication criteria for spirometry, including modified GOLD criteria, in order to detect COPD: data from 5,315 subjects in the PLATINO study.

Authors:  Ana P Luize; Ana Maria B Menezes; Rogelio Perez-Padilla; Adriana Muiño; Maria Victorina López; Gonzalo Valdivia; Carmem Lisboa; Maria Montes de Oca; Carlos Tálamo; Bartolomé Celli; Oliver A Nascimento; Mariana R Gazzotti; José R Jardim
Journal:  NPJ Prim Care Respir Med       Date:  2014-10-30       Impact factor: 2.871

Review 9.  Management of asthma and chronic obstructive pulmonary disease with combination inhaled corticosteroids and long-acting β-agonists: a review of comparative effectiveness research.

Authors:  Douglas W Mapel; Melissa H Roberts
Journal:  Drugs       Date:  2014-05       Impact factor: 9.546

10.  Confirmatory spirometry for adults hospitalized with a diagnosis of asthma or chronic obstructive pulmonary disease exacerbation.

Authors:  Valentin Prieto Centurion; Frank Huang; Edward T Naureckas; Carlos A Camargo; Jeffrey Charbeneau; Min J Joo; Valerie G Press; Jerry A Krishnan
Journal:  BMC Pulm Med       Date:  2012-12-07       Impact factor: 3.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.